Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration **Treatments Trials**


Sharma S, Toth CA, Daniel E, et al. Ophthalmology. 2016;123(4): 865–875.


doi:10.1016/j.ophtha.2015.12.002

In this paper, the researchers described the association between morphologic features on fundus photography (FP), fluorescein angiography (FA), optical coherence tomography (OCT) and visual acuity (VA) in the second year of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).



This was a 2-year randomized trial of ranibizumab and bevacizumab with 3 different dosing regimens







Relative Proportion of Participants (%) With Fluid of Any Type


a decrease in any type of fluid in all treatment groups

When compared with baseline, through week 104, there was





Relative Proportion of Participants (%) With Intraretinal Fluid (IRF)



Fluid of Any Type

70

70

80

75

None


Foveal


(606, 212, 136)

Week 104

70

Nonfoveal





(652, 168, 179)

Week 24

(700, 159, 159)

Week 52

(575, 175, 149)

Week 76

Conclusions A key 1-year study finding was that IRF, as determined by OCT, had a negative impact on VA at all time points examined. The strength of this association increased throughout year 2 of this study. When controlling for other potential confounding variables, IRF was independently associated with worse VA at year 2. Paradoxically, the presence of SRF was associated with better VA at year 2 even when controlling for other potentially confounding variables. The strength of this effect was greater for eyes with foveal SRF and for small amounts of SRF. The reasons for the association between better VA and SRF are unclear.

(687, 164, 179)

Week 12

(183, 545, 403)

Week 0

(623, 211, 265)

Week 4